The United States Patent and Trademark Office (USPTO) has issued patent US12578335B2, titled 'Novel bioprobes for amine oxidase enzymes, and uses thereof,' to Syntara Limited. The patent covers new bioprobes capable of binding to specific amine oxidase enzymes, which can be utilized in methods for detecting and quantifying these enzymes in samples, as well as for assessing their inhibition. The patent was filed on February 5, 2021, and granted on March 17, 2026, with 22 claims.

This patent grant signifies the allowance of intellectual property protection for Syntara Limited's novel technology. While not imposing direct compliance obligations on other entities, it establishes exclusive rights for the assignee. Companies operating in the pharmaceutical or biotechnology sectors, particularly those involved in enzyme research, diagnostics, or drug development targeting amine oxidases, should be aware of this granted patent to ensure they do not infringe upon the protected claims. No immediate compliance actions are required for external parties, but awareness is crucial for ongoing R&D and commercialization strategies.